2023
DOI: 10.26434/chemrxiv-2023-9n5s0
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Antibody-based Imaging of Bioreductive Prodrug Release in Hypoxia

Abstract: Regions of hypoxia occur in most tumors and predict for poor patient prognosis. Hypoxia-activated prodrugs provide an ideal strategy to target the aggressive, hypoxic fraction of a tumor while protecting the normal tissue from toxicity. A key challenge associated with the development of novel hypoxia-activated prodrugs, however, is the ability to visualize the delivery of the prodrug to hypoxic regions and determine where it has been activated. Here we report a modified version of the commonly used nitroimidaz… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 29 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?